Company AnnouncementCOPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting.At the Extraordinary General Meeting the proposal from the Board of Directors on remuneration of the Board of Directors for 2026, including share-based remuneration in the form of restricted stock units, was approved. As a result of the adoption of the proposal, a total of 5,300 restricted stock units were granted to the members of the Board of Directors in

Genmab stock: what the latest trial results mean for investors Genmab (CPSE:GMAB) is suddenly back on many watchlists after two fresh clinical readouts in oncology, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large B cell lymphoma. The EPCORE DLBCL 2 trial, run with AbbVie, reported that epcoritamab plus R CHOP cut the risk of disease progression or death by 51% versus R CHOP alone in patients with higher risk DLBCL. For a late stage blood cancer study, that kind of...

European shares rose to near one-week highs on Tuesday, with the Stoxx 600 up 0.8% to 638.41 points by 0727 GMT for a third straight session of gains.…

Investing.com – Las acciones de Genmab subieron más de un 8% en las primeras operaciones del martes después de que la biotecnológica danesa y AbbVie dijeran que su tratamiento combinado para pacientes recién diagnosticados con un tipo de linfoma reducía el riesgo de progresión de la enfermedad o muerte en un estudio de última fase.